UPDATE
1-Pfizer?s Ibrance drug slows progression of
breast cancer
CHICAGO May 30 (Reuters) - A Phase III trial of Pfizer Inc's
Ibrance showed that, in combination with hormonetherapy, the
drug more than doubled the duration of diseasecontrol for women with the...
